



Françoise BONTEMPS, Associate Member
Eric VAN DEN NESTE, Clinical Investigator



Georges VAN DEN BERGHE, Emeritus Member

Caroline SMAL, Postdoctoral Fellow
Laurent BASTIN-COYETTE, Graduate Student
Emeline de VIRON, Graduate Student
Rachid AMSAILALE, Graduate Student
Angélique AERTS, Technician

NUCLEOSIDE ANALOGUES IN LEUKAEMIA

Our group was initially interested in purine metabolism, particularly adenine nucleotide metabolism, and its genetic defects. Thereafter, we expended our investigations on two therapeutic purine nucleoside analogues, 2-chlorodeoxyadenosine and fludarabine, which have revolutionized the treatment of indolent lymphoproliferative disorders. Despite this activity, clinical resistance to these drugs is frequently observed. The main objectives of our present studies are to unravel the mechanisms leading to resistance to nucleoside analogues and to find novel therapeutic strategies to counteract them, particularly in chronic lymphocytic leukaemia.

In 1997, a collaborative study of the anti-leukaemic purine nucleoside analogues (PNA), 2-chlorodeoxyadenosine (CdA) and fludarabine (Fig. 1), was started with the Department of Haematology of the University Hospital Saint-Luc. These two deoxyadenosine analogues display remarkable therapeutic properties in indolent lymphoid malignancies including hairy cell leukaemia and chronic lymphocytic leukaemia (CLL). Nevertheless, resistance is also observed, and PNA do not confer a survival advantage when compared to more conventional therapies such as alkylating agents. The aims of our studies are to understand the mechanisms that lead to resistance to nucleoside analogues, and to improve their therapeutic efficacy by searching for synergisms with other compounds.

CdA and fludarabine are prodrugs. To exert their antileukaemic effect, they have to be phosphorylated by deoxycytidine kinase (dCK) into nucleoside analogue monophosphates, followed by conversion into di- and triphosphate derivatives. The latter are the active metabolites. They have been shown to inhibit various processes involved in DNA and RNA synthesis. Moreover, they can be incorporated into newly synthesised DNA, causing chain termination. Together, these actions result in arrest of DNA synthesis (replication and repair) and in the progressive accumulation of DNA strand breaks, leading to apoptosis by mechanisms which are not yet entirely clear (1, for a review).




Fig. 1. Structures of deoxyadenosine and analogues

MECHANISMS OF ACTION

F. Bontemps, C. Smal, L. Bastin-Coyette, E. de Viron, A. Aerts, E. Van Den Neste

To improve our understanding of the mechanisms by which CdA induces apoptosis in CLL cells, we study its effects in EHEB cells, a continuous cell line derived from a patient with CLL. The EHEB cell line was found to be less sensitive (10- to 100-fold) to CdA than other human lymphoblastic cell lines. This could be explained by a lower intracellular accumulation of CdATP, the active metabolite of CdA, due to a reduced dCK activity. Unexpectedly, DNA synthesis, measured by thymidine incorporation into DNA, was found to be increased in these cells, up to 2-fold, after a 24 h-incubation with CdA at concentrations close to the IC50 (5 μ M) (2). Analysis by flow cytometry, using double labelling with propidium iodide and bromodeoxyuridine, has also shown that CdA provoked an increase in the proportion of cells in S phase, synthesising actively DNA. These results contrasted with those reported in other leukaemic cell lines, like CCRF-CEM cells, in which CdA inhibits DNA synthesis. Kinetics and synchronisation experiments have shown that the increase in the proportion of cells in S-phase induced by CdA in EHEB cells was due to a stimulation of the progression of cells from G1 to S phase. This unexpected result has

led us to examine the effects of CdA on proteins involved in the regulation of cell cycle, particularly the cyclin-dependent kinases and p21, and to investigate whether this activation of the transition G1-S contributes to CdA-induced apoptosis in EHEB cells.

In parallel, we have analysed the mechanisms of cell death induced by 2-chloroadenosine (2-CAdo) in various types of leukaemic B-cells. This analogue is not activated by dCK, like CdA, but by adenosine kinase. We found that 2-CAdo was efficiently converted into 2-chloroATP, resulting in ATP depletion, as well as in inhibition of DNA, RNA and protein synthesis. 2-CAdo also caused activation of the intrinsic pathway of apoptosis, which was p53-independent and associated with a decline in Mcl-1 protein level. Prevention of ATP loss by inhibition of AMP deaminase reduced apoptosis, indicating that ATP depletion plays an important role in 2-CAdo-induced apoptosis (3).

More recently, we have initiated microarray analyses to identify survival or death pathways that are activated in response to CdA and fludarabine. We intended to compare genes induced or repressed by these PNA in sensitive and refractory CLL patients. We found that, in chemosensitive samples, PNA predominantly increased the expression of p53-dependent genes, among which PLK2 (polo-like kinase

2) was the most highly activated at early time points. Conversely, in chemoresistant samples, p53-dependent and PLK2 responses were abolished. Using qPCR, we confirmed that PNA dose- and time-dependently increased PLK2 expression in chemosensitive but not chemoresistant CLL samples. Analysis of a larger cohort of CLL patients showed that cytotoxicity induced by PNA correlated well with PLK2 mRNA induction. In conclusion, we propose that testing PLK2 activation after a 24-h incubation with PNA could be used to investigate the functional integrity of DNA-damage response pathways in CLL cells, and predict clinical sensitivity to these drugs (4). This study was performed in collaboration with Dr Knoop from the Ludwig Institute for Cancer Research (Brussels). The following step is to investigate the role of PLK2 during PNA-induced apoptosis.

SEARCH FOR POTENTIATION OF ANTILEUKAEMIC EFFECT OF 2-CHLORODEOXYADENOSINE

E. Van Den Neste, C. Smal, F. Bontemps

Some years ago, we have shown that combination of CdA with DNA-damaging agents, such as cyclophosphamide (CP) derivatives (5) or UV-light, resulted in synergistic cytotoxicity in CLL lymphocytes, due to inhibition of DNA repair (6). The *in vitro* synergy between CdA and CP derivatives has provided the rationale for a clinical trial of this combination, which gives encouraging results.

Lately, we have explored the possibility that CdA interacts with the mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/ERK) pathway. We have shown that CdA, at concentrations close to the IC₅₀, activated the ERK pathway in EHEB cells. Because activation of this pathway is assumed to exert anti-apoptotic effect, we combined CdA with inhibitors of the ERK pathway. The latter

were found to enhance CdA-induced apoptosis. These results suggest that the efficacy of CdA could be strengthened by combination with inhibitors of the ERK pathway (7).

REGULATION OF DEOXYCYTIDINE KINASE ACTIVITY

C. Smal, R. Amsailale, A. Aerts, E. Van Den Neste, F. Bontemps

Deoxycytidine kinase (dCK) activates numerous nucleoside analogues used in anti-cancer and antiviral therapy. Studies of the mechanism(s) that control the activity of this enzyme are thus of particular interest. Our study of dCK was initiated by the discovery, by others and by us, that dCK activity can be increased by various genotoxic agents, including CdA, aphidicolin, etoposide, and UV-C irradiation, without an increase of dCK protein level. Therefore, a post-translational activation of dCK by intracellular signalling pathways was suggested. To investigate this hypothesis, we first analyzed the effect of a variety of activators and inhibitors of protein kinases on dCK activity. We found that some of them could modify dCK activity in several types of leukaemic cells, strengthening the hypothesis of a phosphorylation/dephosphorylation process as a mechanism of regulation of dCK activity. Most particularly, our results indicated that dCK could be down-regulated by the JAK/MAPK pathway and that it might be an *in vivo* target of protein phosphatase 2A (8).

We then overexpressed dCK in HEK 293T cells and observed that the enzyme was labeled after incubation with [³²P]orthophosphate, confirming that dCK is a phosphoprotein. Tandem mass spectrometry performed by Dr D. Vertommen and Prof. M.H. Rider from the Horm-Phos unit (de Duve Institute) allowed the identification of four *in vivo* phosphorylation sites, Thr-3, Ser-11, Ser-15 and Ser-74 (Fig. 2). Site-directed mutagenesis demonstra-




Figure 2. Three-dimensional structure of deoxycytidine kinase in complex with ADP and deoxycytidine. The Ser-74 phosphorylation site is located at a very flexible 15-residue insert (Ser-63-Asn-77) easily accessible to cellular protein kinases. The N-terminal extremity of dCK (residues 1-19) was flexible and could not be solved. Therefore, the Thr-3, Ser-11 and Ser-15 phosphorylation sites cannot be exactly located.

ted that Ser-74 phosphorylation was crucial for dCK activity in HEK 293T cells, whereas phosphorylation of other identified sites did not seem essential (9). Phosphorylation of Ser-74 was also observed on endogenous dCK in CCRF-CEM cells and in lymphocytes from CLL patients, in which Ser-74 phosphorylation was increased by several genotoxic agents (UV, etoposide, ...) that enhanced dCK activity, and decreased by sorbitol that diminished dCK activity. Moreover, interindividual variability in dCK activity in CLL lymphocytes could be related to its phosphorylation level on Ser-74 (10). To conclude, our work has demonstrated that dCK activity in leukaemic cells largely depends on the phosphorylation state of Ser-74. We are now attempting to identify the protein kinase(s) and the protein phosphatase(s) that control Ser-74 phosphorylation and the signalling pathways that lead to dCK activation following treatment with DNA damaging agents. Moreover, we are investigating whether

increase of Ser-74 phosphorylation could enhance efficacy of nucleoside analogues in various types of cancer cells.

SELECTED PUBLICATIONS

1. Van Den Neste E, Cardoen S, Offner F, Bontemps F. *Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine.* **Int J Oncology** 2005;27:1123-34.
2. Cardoen S, Van Den Neste E, Smal C, Rosier JF, Delacauw A, Ferrant A, Van den Berghe G, Bontemps F. *Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukaemia cell line EHEB.* **Clin Cancer Res** 2001;7:3559-66.

3. Bastin-Coyette L, Smal-C, Cardoen S, Saussoy P, Van Den Neste E, Bontemps F. *Mechanisms of cell death induced by 2-chloroadenosine in leukemic B-cells*. **Biochem Pharmacol** 2008;75:1451-60.
4. de Viron E, Knoops L, Connerotte T, Smal C, Michaux L, Saussoy P, Vannuffel P, Beert E, Vekemans MC, Hermans C, Bontemps F, Van Den Neste E. *Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response*. **Br J Haematol** 2009;147:641-52.
4. Van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM, Gillis E, Leveugle P, Deneys V, Ferrant A, Van den Berghe G. *Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukaemia cells by 2-chloro-2'-deoxyadenosine*. **Leukaemia** 1999;13:918-25.
5. Van Den Neste E, Cardoen S, Husson B, Rosier JF, Delacauw A, Ferrant A, Van den Berghe G, Bontemps F. *2-Chloro-2'-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukaemia B lymphocytes*. **Leukaemia** 2002;16:36-43.
7. Smal C, Lisart S, Maerevoet M, Ferrant A, Bontemps F, Van Den Neste E. *Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukaemia cell line EHEB*. **Biochem Pharmacol** 2007;73:351-8.
8. Smal C, Cardoen S, Bertrand L, Delacauw A, Ferrant A, Van den Berghe G, Van Den Neste E, Bontemps F. *Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells*. **Biochem Pharmacol** 2004;68:95-103.
9. Smal C, Vertommen D, Bertrand L, Ntamashimikiro S, Rider M, Van den Neste E, Bontemps F. *Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity*. **J Biol Chem** 2006;281:4887-93.
10. Smal C, Van Den Neste E, Maerevoet M, Poiré X, Théate I, Bontemps F. *Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes*. **Cancer Lett** 2007;253:68-73.

Françoise Bontemps

de Duve Institute
Av. Hippocrate 74-75
B - 1200 Brussels

[T] +32 (02) 764 75 68

[F] +32 (02) 764 75 98

[E] francoise.bontemps@uclouvain.be

[W] http://www.deduveinstitute.be/nucleoside_analogues_in_leukaemia.php